SLC10A2

Ileal sodium/bile acid cotransporter · Q12908 · SLC10A2 on Sugi Atlas →

20,346 patent compounds predicted against SLC10A2, 15,011 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL347340 SCHEMBL347340 1.00 20/20
SCHEMBL349299 SCHEMBL349299 1.00 20/20
SCHEMBL349300 SCHEMBL349300 1.00 20/20
SCHEMBL348804 SCHEMBL348804 0.76 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL349001) 0.74 20/20
SCHEMBL347952 SCHEMBL347952 0.67 20/20
SCHEMBL349650 SCHEMBL349650 0.67 20/20
SCHEMBL366859 SCHEMBL366859 0.67 20/20
SCHEMBL347797 SCHEMBL347797 0.65 20/20
SCHEMBL348624 SCHEMBL348624 0.65 20/20
SCHEMBL348841 SCHEMBL348841 0.64 20/20
Bromide Bromide (SCHEMBL347142) 0.63 20/20
SCHEMBL349686 SCHEMBL349686 0.63 20/20
SCHEMBL348852 SCHEMBL348852 0.62 20/20
SCHEMBL919677 SCHEMBL919677 0.62 20/20
SCHEMBL347586 SCHEMBL347586 0.61 20/20
SCHEMBL919249 SCHEMBL919249 0.61 20/20
Bromide Bromide (SCHEMBL349464) 0.59 20/20
SCHEMBL366691 SCHEMBL366691 0.59 20/20
SCHEMBL920147 SCHEMBL920147 0.59 20/20

Clinical trials — most relevant to SLC10A2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment of Bile Acid Diarrhoea With Atorvastatin PHASE4RECRUITING
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation. PHASE4COMPLETED
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes PHASE3NOT_YET_RECRUITING
BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases PHASE2/PHASE3WITHDRAWN
Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis PHASE2COMPLETED
Secretin in Ex-situ Liver Perfusion PHASE1/PHASE2ENROLLING_BY_INVITATION
Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)? PHASE2COMPLETED
Cheno Effect on Transit in Health and IBS-C PHASE2COMPLETED
Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis PHASE2COMPLETED
Obeticholic Acid in Bile Acid Diarrhoea PHASE2COMPLETED
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin PHASE2NOT_YET_RECRUITING
Bioavailability of Paracetamol, Amoxicillin and Talinolol Before, Immediately and One Year After Gastric Bypass Operation PHASE1COMPLETED
Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 Diabetics PHASE1COMPLETED
Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin PHASE1COMPLETED
Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT EARLY_PHASE1COMPLETED
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals nanENROLLING_BY_INVITATION
Regulation of Human Intestinal Bile Acid Transport in Health and Disease nanCOMPLETED
FGF19 in Obstructive Cholestasis: Unveil the Signal nanUNKNOWN
Gut Transit Effect on Enterohepatic Circulation nanCOMPLETED
Gene Expression in Inflammatory Bowel Disease nanENROLLING_BY_INVITATION
Bile Acids Metabolism and Genetic Mutation Profile in the Intrahepatic Cholestasis of Pregnacy in Indian Population nanRECRUITING
The Role of Faecal Bile Acids in the Management of Bile Acid Diarrhoea nanCOMPLETED
Effects of Colesevelam HCl On Bile Acid Kinetics nanCOMPLETED
Pediatric Evaluation and Registry for Liver Cholestasis in Canada nanRECRUITING
Intralumenal Effects on Cholesterol Absorption/Synthesis nanCOMPLETED
Mechanisms of Glucose Lowering Effect of Colesevelam HCl nanCOMPLETED
Expression of BCRP in Icteric Patients nanCOMPLETED
The Microbiome Composition in Women With Recurring Intrahepatic Cholestasis of Pregnancy (ICP) nanCOMPLETED
A Trial of Taurine Supplementation in Parenteral Nutrition 1 nanUNKNOWN
The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a SLC10A2 binder may also engage these)

ProteinNameSimilarity
Q62633 1.000 Q62633 →
P70172 1.000 P70172 →
Q60414 1.000 Q60414 →
Q28727 0.999 Q28727 →
SLC10A6 Sodium-dependent organic anion transporter 0.958 landscape →
Q5R6B8 0.955 Q5R6B8 →
SLC9B2 Sodium/hydrogen exchanger 9B2 0.952 landscape →
A6QP84 0.949 A6QP84 →
Q3UEZ8 0.948 Q3UEZ8 →
Q5PT56 0.948 Q5PT56 →
A0A6P3HVI0 0.948 A0A6P3HVI0 →
Q5BKR2 0.947 Q5BKR2 →
Q96EP9 0.944 Q96EP9 →
A4IHB9 0.942 A4IHB9 →
Q70EX6 0.941 Q70EX6 →
Q9CXB2 0.940 Q9CXB2 →
Q6DEJ6 0.940 Q6DEJ6 →
Q91WC7 0.938 Q91WC7 →
Q0IHM1 0.936 Q0IHM1 →
Q5U3U7 0.936 Q5U3U7 →
Q8NA29 0.936 Q8NA29 →
Q8TF71 0.936 Q8TF71 →
Q8BH31 0.936 Q8BH31 →
Q3MHW6 0.936 Q3MHW6 →
Q9DA75 0.935 Q9DA75 →
A1L1W9 0.935 A1L1W9 →
O35874 0.934 O35874 →
Q8NHS3 0.934 Q8NHS3 →
Q9H841 0.933 Q9H841 →
Q0VA82 0.933 Q0VA82 →